Spero Therapeutics Enters License Agreement With Innovent Biologics For Exclusive Rights To Develop, Research, Manufacture, And Commercialize SP001 Globally Ex-China

Loading news article.

Spero Therapeutics Enters License Agreement With Innovent Biologics For Exclusive Rights To Develop, Research, Manufacture, And Commercialize SP001 Globally Ex-China | WAPE

Spero Therapeutics Enters License Agreement With Innovent Biologics For Exclusive Rights To Develop, Research, Manufacture, And Commercialize SP001 Globally Ex-China

Article summary

Related companies

Comments —